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Abstract
We propose a two-stage design for a clinical trial with an early stopping rule for safety. We
use different criteria to assess early stopping and efficacy. The early stopping rule is based
on a criteria that can be determined more quickly than that of efficacy. These separate
criteria are also nested in the sense that efficacy is a special case of, but not identical to,
the early stopping criteria. The design readily allows for planning in terms of statistical
significance, power, and expected sample size necessary to assess an early stopping rule.
This method is illustrated with a Phase II design comparing patients treated for lung cancer
with a novel drug combination to those treated using historical control. In this example, the
early stopping rule is based on the numbers of patients who exhibit progression-free survival
(PFS) at 2 months post treatment follow-up and efficacy is judged by the number of patients
who have PFS at 6 months.
Keywords: lung cancer; power; sample size; early stopping rule; discrete distribution
1 Introduction
A fundamental design feature of the two-stage Phase II clinical trial is the convenient early
stopping rule that prevents us from exposing excessive numbers of patients to a possibly
inferior treatment. In the traditional two stage designs [1], we use the same criteria for
early stopping as with the final test of efficacy. Simply, a number of patients are initially
enrolled in Stage 1. Then we wait to see their outcome before enrolling the remainder of
the subjects in Stage 2. The criteria for advancing from Stage 1 to Stage 2 is based on
a (statistically) large number of patients achieving the same favorable criteria in Stage 1
as will be latter examined for efficacy of treatment at the conclusion of Stage 2. An ideal
choice of criteria of outcome for such a design is one that can be assessed quickly. A good
example of favorable criteria might include response to therapy, as determined a few weeks
after treatment, verified by a CT scan. The motivation for our present work is the setting
where the efficacy determination can only be made after a lengthy follow-up time on each
patient.
Our motivating problem came about in a study of a novel drug combination treatment of
lung cancer in which our efficacy criteria is 6 month PFS in geriatric patients. This criteria
would create a long delay between Stage 1 and Stage 2 as we wait to observe the outcomes
of the Stage 1 patients before enrolling additional patients into Stage 2. Using traditional
designs [1], there could be up to an 6 month delay in accrual until the outcomes of the
Stage 1 patients become available. One solution to this delay would be to enroll all patients
without an early stopping rule, but such a design eliminates any safeguards of exposing
excessive numbers of patients to an inferior or harmful treatment. Another solution would
be to continue accruing patients into Stage 2 while waiting for those in Stage 1 to achieve
their endpoints. This approach also has the potential of exposing too many patients to a
possibly inferior treatment.
Our proposed solution is to use a criteria for early stopping that is different from the
criteria used to assess efficacy. We want these separate criteria to be nested in the sense that
the efficacy criteria is a special case of the safety criteria. That is, the criteria for efficacy
can not be achieved if the patient fails the shorter term, safety outcome. In our specific
application in Section 3, the efficacy measure is 6 month PFS and we will use the rate of
2 month PFS as the criteria for early stopping. The estimates of 2- and 6-month historical
PFS rates are based on a published Kaplan-Meier survival curve Ŝ(t) estimating PFS times.
The published survival curve Ŝ provides a standard-of-care comparison and provides us with
the flexibility to choose any pair of PFS times t1 ≤ t2 and the corresponding survival rates.
The large literature written on two-stage designs attests to their popularity in clinical
trial practice. We cite only some of the literature here. The original idea of the two-stage
design for Phase II trials is attributed to R.Simon [1], with other developments building
on the original idea [2– 8]. There are review articles [9– 12] covering Phase II designs and
issues in clinical trials, more generally. The use of historical control data suggests Bayesian
approaches [13– 17]. Estimation of parameters [18, 19] is not a simple task because of the
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complex sampling distributions that are involved. There are generalization to three or more
stages [21, 20]. There is also some work [22, 23] in how Phase II endpoints can help in
planning subsequent Phase III studies.
The present manuscript is concerned with separate criteria for safety and efficacy. Thall
and Cheng [24, 25] also consider clinical trial designs with separate parameters for safety
and efficacy for events that are not nested, as developed here. Similarly, small sample size
studies with multiple safety observations on each subject are considered as well [26].
In Section 2 we provide the necessary notation and derive all of the mathematical for-
mulæ. In Section 3 we provide practical guidance using the parameters of the proposed lung
cancer trial as an example. Section 4 compares the traditional two-stage design due to Simon
[1] with the designs proposed here.
2 Notation and basic results
We begin the development of the proposed design by considering rates of overall survival
or PFS at two follow-up times t1 ≤ t2. Survival or PFS at two different times is the most
obvious example of a pair of nested criteria that could fit the framework of this design. Our
results are not specific to these choices however. Nevertheless, we will continue the narrative
describing the outcomes as PFS at two different time points.
In typical planning for the Phase II studies proposed here, there will be a published
Kaplan-Meier survival (or PFS) estimate Ŝ(t) that we will use as a comparison to the
established standard of care. The new treatment will be compared to this estimate of a
historical control. The estimated rates of survival, p̂i = Ŝ(ti), (i = 1, 2) obtained from this
survival curve provide us with a pair of parameters needed to design our study. We will omit
the carets on p̂1 and p̂2 but the reader should keep in mind that these historical control
rates are usually published estimates, as is typically the case with Phase II studies.
The null hypothesis that we wish to test is that overall survival or PFS at time t2 is
equal to p2 and the alternative hypothesis is that this rate is greater than p2. The survival
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rate p1 at time t1 is a safety parameter that is used to judge the early stopping rule. These
rates satisfy 0 ≤ p2 ≤ p1 ≤ 1. In the traditional Simon two-stage design [1] we have t1 = t2
and p1 = p2 because the safety and efficacy criteria are identical. We will discuss these
parameters again and provide a specific example in Section 3.
We will need to identify study parameters for a design that terminates the clinical trial
early if our observed survival fraction at time t1 is not at least as large as p1. Let n1
denote the sample size of patients enrolled in Stage 1 of the study. Let the random variable
X1 denote the number of these patients who have successful outcomes after each has been
followed for a duration of time t1.
The random variable X1 has a binomial distribution with parameters n1 and p1. For
an a priori fixed cut off value r1, if X1 ≥ r1 then the trial will continue from Stage 1 into
Stage 2. The design parameter r1 will need to be determined as part of the clinical trial
planning process. The X1 successful patients in Stage 1 will continue to be followed up
to time t2 if we decide to proceed into Stage 2. We will come back to these subjects in a
moment. If X1 < r1 then the trial will terminate early.
In Stage 2 we enroll additional patients, follow each of them for a longer period of time
t2, and use their responses to test the null hypothesis for efficacy. Specifically, in Stage 2,
an additional n2 patients will be enrolled and each will be followed for a minimum period
of time t2 where t2 ≥ t1. Let the random variable X2 denote the number of successes
among these Stage 2 patients. The distribution of X2 is binomial with index parameter n2
and probability of success p2, again assuming the historical rates for comparison as the null
hypothesis.
In addition to these X2 successes, there will be a random variable, denoted by X12, of
successes at time t2 who were initially enrolled in Stage 1. That is, X12 is the conditional
number of successes at time t2 given that they were successes at time t1. At the conclusion
of Stage 2, we will declare the new treatment successful (reject the null hypothesis) if the
total number of successes (X12 + X2) at time t2 exceeds a study parameter r2 that is
determined a priori. Fig. 1 is a useful representation of the time line for this design.
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Given these notations, we can proceed with the necessary derivations for evaluating the
operating characteristics of a proposed clinical trial design of this form.
The probability of early termination is
Pr[ Early termination ] = Pr[X1 < r1 ]
where X1 has a binomial distribution with index n1 and probability parameter p1.
From this expression we also have a bound on the expected sample size:
Expected sample size ≤ n1 + n2 (1− Pr[ Early termination ]). (1)
Expression (1) is an upper bound on the expected sample size. A more useful estimate
models the rate of accrual necessary until r2 successes are observed at follow-up time t2. In
the Appendix, we provide details for obtaining the expectation of the minimum number of
Stage 1 patients needed in order to be able to make a decision whether or not to continue
into Stage 2.
Let us next derive an expression for the probability that we reject the null hypothesis
(H0):
Pr[ reject H0 ] = Pr[X12 +X2 ≥ r2 ].
We first condition on the number of successes X1 in Stage 1:
Pr[ reject H0 ] =
∑
x1
Pr[X1 = x1 ] Pr[X12 +X2 ≥ r2 | x1 ]
Since X12 and X2 are independent, we can write the distribution of their sum as a
convolution:
Pr[ reject H0 ] =
∑
x1
Pr[X1 = x1 ]
∑
x12
Pr[X12 = x12 | x1 ] Pr[X2 ≥ r2 − x12 ]
The conditional distribution of X12 given X1 is binomial with index parameter X1
and probability parameter equal to p2/p1. The distribution of X2 is independent of both
X1 and X12.
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This gives us
Pr[ reject H0 ] =
n1∑
x1 =
max(r1, r2 − n2)
Pr[X1 = x1 ]
x1∑
x12 =
max(0, r2 − n2)
Pr[X12 = x12 | x1 ]
n2∑
x2 =
max(0, r2 − x12)
Pr[X2 = x2 ] (2)
The limits of the summation must take into account both the decision to continue
sampling after Stage 1 (i.e. X1 ≥ r1) as well as the rejection of the null hypothesis at the
end of Stage 2 (i.e. X12 + X2 ≥ r2). The lower limits of each summation in (2) are not
greater than the upper limits so long as there are valid design criteria in n1, n2, r1, and r2.
The limits and ranges for these parameters are summarized in Table 1. This table includes a
summary of the distributions needed to compute this probability. The R programs are also
available by request from the author.
For specified values of (p1, p2) we find values of the design parameters (n1, n2, r1, r2) so
that the probability in (2) does not exceed a specified significance level, α. These parameters
allow us to calculate the probability of early termination and the bound on the expected
sample size given at (1). The following section describes several such examples.
The power of the study is the probability of rejecting the null hypothesis. The probability
in (2) is a general statement, valid for any values of (p1, p2) satisfying 0 ≤ p2 ≤ p1 ≤ 1.
In addition to describing the statistical significance at the null hypothesis, we can consider
other parameter values as well, and use this same expression to determine the power at
other choices of (p1, p2). The designs proposed in the following section are geared towards
demonstrating an increase in the value of the efficacy parameter p2 while holding the safety
parameter p1 fixed. Of course, we can also use (2) to describe power against other alternative
hypotheses as well, where p1 as well as p2 are allowed to vary between hypotheses. The
following section includes an example of varying both p1 and p2, under the alternative
hypothesis.
We also have:
Power ≤ Pr[ Early stopping ] (3)
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because we can not reject the null hypothesis if we decide to terminate the clinical trial early.
This bound proves to be critical in choosing a suitable design, as we show next.
3 Design Guidance
The previous section provides the mathematical background needed to assess the character-
istics of any design and also allows us to compare one design with another. In this section we
provide some guidance on how to select a useful and practical design. We will demonstrate,
in a specific example, that the same criteria used in selecting a Simon two-stage design is
not always useful in the present setting.
Let us consider a specific set of parameter values in order to describe these guidelines.
In this illustration we restrict designs to those with a maximum of n1 + n2 = 36 patients to
be enrolled. The figure of 36 is in line with the size of designs for Phase II studies that we
regularly conduct at the Yale Comprehensive Cancer Center. Typical of Phase II studies,
we also use a statistical significance of α = .1.
To motivate the use of the methods developed in this work, consider the safety parameter
p1 = .8 to model the PFS rate at follow-up time t1 = 2 months of Stage 1. We also assume
p2 = .2 to describe the longer-term PFS rate at t2 = 6 months in Stage 2. These times and
rates are suggested by published survival curves [27, 28] that we will use as the basis of our
historical control values. All of these parameter values are typical for the type of studies
that we conduct.
Let us begin by considering every possible choice of non-negative integer values of n1
and n2 such that n1 + n2 = 36. For every choice of n1 and n2 we also look at all possible
choices of cut-off values r1 and r2 and choose values that achieve one of several different
characteristics that are detailed in this section. Table 2 summarizes all of the designs selected
and discussed in this section. In order to provide guidance on how to select a suitable design,
let us begin by using those same criteria that are usually chosen when planning a Simon
two-stage design [1].
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Largest statistical significance. We can not achieve a statistical significance of exactly
α because of the discrete distributions involved. The exact significance level will always be
slightly lower than this desired value. This results in a test that is considered ‘conservative’
because the exact statistical significance is lower than the claimed α level. The design with
the largest statistical significance, without exceeding α = .1, is labeled as ‘A’ in Table 2. A
test with lower statistical significance will typically be at a disadvantage when comparing
its power with a test with a higher significance levels, all other things remaining equal. This
disadvantage, however, is only relevant to a small and unimportant range of the parameter
values, as we see in Fig. 2, when we compare the power of this design with that of others
that are suggested, below.
Lowest expected sample size. This design criteria is also called ‘optimal’ in the language
of traditional Simon two-stage Phase II designs. This design is listed as ‘B’ in Table 2. Such
optimal designs offer efficiency in terms of lower expected costs and numbers of patients
accrued. In Table 2 we calculate the expected sample size using the upper bound provided
at (1).
Highest probability of early termination. Also called ‘minimax’ because this minimizes
the probability of the largest possible sample size. This is listed as design ‘C’ in Table 2.
These designs are similar to the optimal designs because these aim to minimize the maximum
possible costs.
Balanced: n1 = n2. In a balanced design, equal numbers of patients are enrolled in
Stages 1 and 2. Intuitively, such a design places equal emphasis on safety and efficacy. This
is listed as design ‘D’ in Table 2. Balanced designs suggest that we place equal effort into
demonstrating both safety and efficacy.
In Table 2 we can see that the four designs A–D all have a probability of early stopping
greater than .89. If only p2 varies between the null and alternative hypotheses, then the
power can not exceed .11 in any of these designs because of the bound on power given
by (3). One way to raise the power is to consider other alternative hypotheses in which p1
also increases. This was not part of the original hypothesis being tested but could certainly
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be incorporated into the design for planning purposes. In the following section we provide
an example of how the power is affected by varying both p1 and p2.
Designs C and D in Table 2 also have values of r2 = 0. This is an unrealistic parameter
value because if we decide to progress from Stage 1 to Stage 2, then we will always reject
the null hypothesis. In other words, all of the statistical significance is determined in the
safety portion of the trial, and not the efficacy portion. This explains why the power of these
designs is so low for testing an alternative hypothesis of increased value of p2. The designs
A–D, based on the criteria that proved useful when planning a Simon two-stage trial all have
serious shortcomings, in terms of low power. We will next introduce another set of useful
criteria.
In light of (3), we propose limiting the probability of early stopping to values in the
interval (.05, .2). The designs proposed here provide separate measures of safety and efficacy.
If the safety parameter of the proposed study is reasonably close to p1 then we should not be
too eager to terminate the study early. Our principal concern in Stage 1 is testing whether
the safety rate p1 is lower than the historical rate. In Fig. 3 we plot the probability of early
termination of the trial for different values of p1.
The statistical significance can be relaxed and we should consider any value between
(.085, .1) as reasonably close to acceptable. We want to make an early decision whether or
not to progress from Stage 1 to Stage 2, so we also suggest that n1 be much smaller than n2.
In the specific suggested designs (E–H) of Table 2 we only include designs with n1 ≤ n2/2.
For all designs with 36 patients, there are four designs that meet these suggested criteria
and these are listed as E–H in Table 2.
Table 2 illustrates the power for an alternative hypothesis of p2 = .4 for each of the
designs listed. Clearly, designs E–H have much greater power than A–D. This difference
is explained by the bound on power given at (3). The large difference in power is also
demonstrated in Fig. 2 where we can see the power at other values of p2. There is a large
difference between the power of designs A–D and E–H but negligible differences in power
within each of these two groups of designs.
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The probability of early stopping in Stage 1 is plotted in Fig. 3 for the designs A–H
listed in Table 2. Designs A–D have high probabilities of stopping early at the historical
PFS rate of p1 = .8 but this also results in greatly reduced power. Designs E–H were
chosen to have early stopping probabilities between .05 and .2 for a PFS rate of p1 = .8
at follow-up time t1 = 2 months. (These lmits are indicated with dotted lines.) Designs
E–H have increasing numbers of observations n1 assigned to Stage 1, and consequently have
monotonically greater chances of stopping early at values of p1 lower than .8.
Designs E–H have negligible differences in power so the choice of which one to use
has more to do with our relative concerns for safety and the probability of inadvertently
terminating the trial early for a safe drug. Specifically, greater concerns for safety would
prefer smaller values of n1 so an early termination decision for a truly dangerous treatment
would be reached sooner.
Our planning may also include varying both p1 and p2 between hypotheses. In this
case, Fig. 4 provides a comprehensive display of power for design F, as an example. The null
hypothesis in this case (p1 = .8 and p2 = .2) is indicated. In this figure, we can consider
the power at any other pair of parameter values satisfying 0 ≤ p2 ≤ p1 ≤ 1.
4 Discussion
To complete a discussion of designs for clinical trials, let us add three others that are not
of the form described in Section 2. These three designs (labeled X, Y, and Z) do not have
separate criteria for stopping and efficacy: these two criteria are the same. In terms of the
notation in Section 2, these three designs use PFS at t1 = t2 and p1 = p2 = .2. The design
‘X’ in Table 2 is a simple binomial sampling with no early stopping and a sample of size
36 patients. If 11 or more patients have PFS at time t2 (which occurs with probability .2
under the null hypothesis) then we reject that hypothesis at significance level .0889.
The last two designs listed in Table 2 are traditional Simon, two-stage designs. Design
‘Y’ is the “optimal” design with a maximum of 37 patients and design ‘Z’ is the “minimax”
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design with 36 patients. These two Simon designs and their powers were calculated using
the clinfun package in R.
The Simon two-stage design [1] is a special case of the designs proposed here with
t1 = t2 and p1 = p2. The Simon design uses the same criteria for early stopping and
efficacy. Specifically, the traditional Simon design counts all of the safety successes (X1)
towards rejecting the null hypothesis, and, consequently should have greater power than
the designs proposed here, but as we see in Fig. 2, this improvement is modest. Similarly,
the Simon designs with comparable sample sizes will also have greater probability of early
termination under the null hypothesis, again, because early stopping and efficacy decisions
are based on the same outcomes. The binomial design (X) also has high power but lacks
any early stopping rule.
The advantage of the designs proposed here (labeled E–H) allow the early termination
decision to be made earlier and with a shorter delay between the accrual of Stages 1 and 2.
The power of all designs in Table 2 is plotted in Fig. 2. As pointed out earlier, designs A–D
have negligible power. In Fig. 2 we see that the designs proposed (E–H) have slightly lower
power than the binomial and Simon designs (X–Z) but as a trade-off, have a much shorter
time to early stopping for safety. Withing these groups of designs (E–H) and (X–Z), there
are negligible differences in power.
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Appendix: Distribution of the Smallest Sample Size in
Stage 1
We may be able to decide early either to continue to Stage 2 or else to terminate before all of
the n1 Stage 1 patients are enrolled. Specifically, as soon as either r1 Stage 1 successes or
else n1−r1+1 failures are observed then we have sufficient data to make the decision whether
to continue or terminate (respectively) without having to wait to observe the remainder of
the Stage 1 subjects.
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Begin by considering a more general result. Let Z1, Z2, . . . denote a sequence of indepen-
dent, identically distributed Bernoulli random variables with Pr[Zi = 1] = p for probability
parameter p (0 ≤ p ≤ 1). For non-negative integer values s and t, let Y denote the small-
est integer value such that {Z1, . . . , ZY } contains either s ones (successes) or else t zeros
(failures).
The distribution of Y has support on integer values in the range
min(s, t) ≤ Y ≤ s+ t− 1. (4)
If ZY = 1 then this represents the s−th success and Y − s has a negative binomial
distribution with
Pr[Y = s+ j and ZY = 1 ] =
(
s+ j − 1
s− 1
)
ps(1− p)j (5)
for j = 0, 1, . . ..
Similarly, if ZY = 0 then Y − t has a negative binomial distribution with
Pr[Y = t+ j and ZY = 0 ] =
(
t+ j − 1
t− 1
)
pj(1− p)t (6)
for j = 0, 1, . . ..
The expressions (5) and (6) represent probabilities of mutually exclusive events so the
distribution of Y is found as the sum of these two probabilities, restricted to the range of
Y satisfying (4). This derivation was verified by extensive simulations, not presented here.
For the special case of s = t, the distribution of Y is the riff-shuffle, or minimum negative
binomial distribution [29]. Similar derivations of the closely related maximum negative
binomial discrete distributions also appear in [30, 31]. The distribution of Y does not have
a simple, closed form but can easily be calculated numerically.
From this general result, we can find an expression for the expectation of the minimum
number of patients necessary in Stage 1 in order to reach any early decision. We obtain the
distribution of the number of these patients necessary to either continue on to Stage 2 or
else terminate the study early by setting p = p1, s = r1 and t = n1 − r1 + 1.
15
Table 3 gives the expected value and standard deviation of the minimum number of
patients required to reach either decision in Stage 1 for designs E–H.
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Table 1: Design parameters, outcomes, their ranges, and interpretations
Parameters Ranges Interpretation
t1, t2 0 ≤ t1 ≤ t2 Follow-up times on study in Stage 1 and Stage 2
n1, n2 Non-negative Sample sizes in Stages 1 and 2
integers
p1, p2 0 ≤ p2 ≤ p1 ≤ 1 Probability of successful outcomes
at follow-up times t1 and t2.
r1, r2 Non-negative r1 is the minimum number of successes in at time t1
integers in Stage 1 for continuing from Stage 1 to Stage 2
0 ≤ r1 ≤ n1 r2 is the minimum number of successes at follow-
0 ≤ r2 ≤ n1 + n2 up time t2 needed to reject the null hypothesis
Outcome
variables
Xi 0, 1, . . . , ni Number of the successes in Stage i
i = 1, 2 Independently distributed as Binomial (ni, pi)
X12 0, 1, . . . , X1 Number of the X1 successes at time t1 in Stage 1 who
later become Stage 2 successes at follow-up time t2.
Distributed as Binomial (X1, p2/p1) given X1
17
Table 2: Details of selected designs with no more than n1 + n2 = 36 patients, maximum
significance level of .1, safety parameter p1 = .8, and null hypothesis p2 = .2. Designs
A–D follow traditional guidelines and designs E–H are suggested in Section 3. The expected
sample size is the upper bound given at (1). The power is for the alternative hypothesis
with p2 = .4.
Expected Probability Power
Label: Exact sample of early for
Description n1 n2 r1 r2 α size stopping p2 = .4
A: Highest α 31 5 28 5 .09997 31.54 .893 .107
B: Lowest expected
sample size 9 27 9 7 .0898 12.62 .866 .134
C: Highest probability
of early termination 32 4 29 0 .0931 32.37 .907 .093
D: Balanced: n1 = n2 18 18 17 0 .0991 19.78 .901 .099
Suggested designs:
E: 5 31 3 11 .0858 34.20 .058 .861
F: 8 28 5 11 .0862 34.42 .056 .863
G: 11 25 7 11 .0868 34.74 .050 .869
H: 12 24 8 11 .0858 34.26 .073 .851
Other designs for t1 = t2 and p1 = p2 = .2.
X: Binomial – 36 – 11 .0889 36. 0 .910
Y: Simon optimal 17 10 3 10 .0948 26.02 .549 .903
Z: Simon minimax 19 15 3 10 .0861 28.26 .455 .902
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Table 3: Expected value and standard deviation of the minimum number of patients nec-
essary to reach any decision in Stage 1 with p1 = .8. The distribution is derived in the
Appendix.
Expected Standard
Design n1 r1 value deviation
E 5 3 3.63 .73
F 8 5 6.11 1.00
G 11 7 8.60 1.23
H 12 8 9.76 1.26
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Figure 1: Graphical schematic of notation for follow-up times, numbers of patients enrolled,
outcome classifications and their binomial probabilities. At the conclusion of Stage 1, at
follow-up time t1, there are x1 successes and we need a minimum of r1 of these to continue
to Stage 2. At follow-up time t2 there are x12 + x2 successes and we need a minimum of
r2 of these to reject the null hypothesis.
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Figure 2: Power of designs listed in Table 2 for a fixed value of the safety parameter p1 = .8.
The null hypothesis is p2 = .2 and the significance level is α = .1.
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Figure 3: Probability of early termination for designs in Table 2. Suggested designs E–H are
selected to have early termination probabilities between .05 and .2 at p1 = .8. These limits
are given with dotted lines.
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Figure 4: Probability of rejecting the null hypothesis for design ‘F’ in Table 2. The location
of the null hypothesis is indicated.
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